Factors affecting compliance in colorectal cancer screening. Results of a study performed in Ballarat
- PMID: 3713601
- DOI: 10.5694/j.1326-5377.1986.tb112341.x
Factors affecting compliance in colorectal cancer screening. Results of a study performed in Ballarat
Abstract
Non-compliance in screening programmes for colorectal cancer is likely to be the most important factor limiting the impact of screening on mortality. This study aimed to determine risk factors and correlates of compliance that could be readily identified by general practitioners. A total of 581 eligible subjects aged 40 to 75 years completed a questionnaire that covered demographic factors, personal medical history, family history of colorectal cancer and smoking status. Faecal occult blood tests were then offered by the general practitioner and compliance correlated with responses. The over-all compliance was 44% and increased to 51% for those who accepted the self-testing kit at consultation. For men, compliance increased with increasing level of education and was significantly greater for non-smokers than for smokers. For women, compliance increased with increasing age, and was greater for those with either symptoms and/or a family history of colorectal cancer. A doctor group-practice factor appeared to influence acceptance versus refusal of the test kit from the doctor. A triage approach to screening in general practice may improve over-all compliance and the yield of tumours. With this strategy, patients at high risk (for example, those with a family history of colorectal cancer or in older age groups) are identified first. Particular attention should be given during consultation to those at high risk who have poor compliance profiles (for example male smokers with a family history of colorectal cancer). High-risk subjects with high compliance profiles would need less attention and low-risk individuals would need least attention.
Similar articles
-
A comparison of methods for increasing compliance within a general practitioner based screening project for colorectal cancer and the effect on practitioner workload.J Epidemiol Community Health. 1988 Mar;42(1):66-71. doi: 10.1136/jech.42.1.66. J Epidemiol Community Health. 1988. PMID: 3418289 Free PMC article. Clinical Trial.
-
Self-administered faecal occult blood tests do not increase compliance with screening for colorectal cancer: results of a randomized controlled trial.Eur J Cancer Prev. 1993 Jul;2(4):301-5. doi: 10.1097/00008469-199307000-00003. Eur J Cancer Prev. 1993. PMID: 8358281 Clinical Trial.
-
Involvement of general practitioners in mass screening. Experience of a colorectal cancer mass screening programme in the Calvados region (France).Eur J Cancer Prev. 1993 May;2(3):229-32. doi: 10.1097/00008469-199305000-00006. Eur J Cancer Prev. 1993. PMID: 8490541
-
Occult blood screening for colorectal carcinoma: a critical review.Gastroenterology. 1985 Mar;88(3):820-37. doi: 10.1016/0016-5085(85)90158-1. Gastroenterology. 1985. PMID: 3917961 Review.
-
[Mass screening of colorectal cancer: where are we up to?].Bull Cancer. 1996 Sep;83(9):746-9. Bull Cancer. 1996. PMID: 8952651 Review. French.
Cited by
-
The pros and cons of fecal occult blood testing for colorectal neoplasms.Cancer Metastasis Rev. 1987;6(3):397-411. doi: 10.1007/BF00144272. Cancer Metastasis Rev. 1987. PMID: 3319274 Review.
-
On attitudes about colorectal cancer screening among gastrointestinal specialists and general practitioners in the Netherlands.World J Gastroenterol. 2006 Aug 28;12(32):5201-4. doi: 10.3748/wjg.v12.i32.5201. World J Gastroenterol. 2006. PMID: 16937533 Free PMC article.
-
Factors Associated With Fecal Calprotectin Sample Collection Compliance: An IBD Center Quality Improvement Project.Crohns Colitis 360. 2022 Dec 3;4(4):otac042. doi: 10.1093/crocol/otac042. eCollection 2022 Oct. Crohns Colitis 360. 2022. PMID: 36778515 Free PMC article.
-
Patient compliance with screening for fecal occult blood in family practice.CMAJ. 1987 Aug 1;137(3):195-8. CMAJ. 1987. PMID: 3607662 Free PMC article.
-
Compliance with the faecal calprotectin test in patients with inflammatory bowel disease.United European Gastroenterol J. 2017 Aug;5(5):702-707. doi: 10.1177/2050640616686517. Epub 2017 Feb 6. United European Gastroenterol J. 2017. PMID: 28815034 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources